Characteristic | EHR/QI (N = 624) | All stage I-III VACCR (N = 4,870) | p-value | VA administrative data (N = 618) | EHR/QI vs. VA administrative data | VA Central Cancer Registry (N = 413) | EHR/QI vs. VA Central Cancer Registry |
---|---|---|---|---|---|---|---|
Demographic | |||||||
Age at diagnosis – median (q1, q3) | 69.0 years (60.3, 78.1) | 69 years (60,77) | 0.64 | N/A | N/A | 69 years (60, 78) | 98.3 % (406 / 413) |
Date of birth - % (n / N) | 98.7 % (610 / 618) | N/A | |||||
Date of death - % (n / N) | 98.1 % (606 / 618) | N/A | |||||
Gender - % (n / N) | 0.84 | 100 % (618 / 618) | 100 % (413 / 413) | ||||
Male | 98.1 % (612 / 624) | 97.9 % (4,768 / 4,870) | 98.2 % (607 / 618) | 99.0 % (409 / 413) | |||
Female | 1.9 % (12 / 624) | 2.1 % (102 / 4,870) | 1.8 % (11 / 618) | 1.0 % (4 / 413) | |||
Unknown | 0.0 % (0 / 624) | 0.0 % (0 / 4,870) | 0.0 % (0 / 618) | 0.0 % (0 / 413) | |||
Race - % (n / N) | 0.27 | 93.0 % (213 / 229) | 98.5 % (392 / 398) | ||||
White | 80.6 % (503 / 624) | 81.8 % (3,986 / 4,870) | 30.6 % (189 / 618) | 80.1 % (331 / 413) | |||
Black | 12.8 % (80 / 624) | 15.2 % (739 / 4,870) | 7.0 % (43 / 618) | 14.8 % (61 / 413) | |||
Other | 4.2 % (26 / 624) | 1.0 % (24 / 4,870) | 0.3 % (2 / 618) | 2.9 % (12 / 413) | |||
Unknown | 2.4 % (15 / 624) | 2.1 % (100 / 4,870) | 62.1 % (384 / 618) | 2.2 % (9 / 413) | |||
Marital status - % (n / N) | 0.73 | 91.4 % (512 / 560) | 95.2 % (357 / 375) | ||||
Single | 39.9 % (249 / 624) | 39.1 % (1,905 / 4,870) | 51.6 % (319 / 618) | 48.9 % (202 / 413) | |||
Married | 50.8 % (317 / 624) | 51.7 % (2,517 / 4,870) | 48.4 % (299 / 618) | 51.1 % (211 / 413) | |||
Unknown | 9.3 % (58 / 624) | 9.2 % (448 / 4,870) | 0.0 % (0 / 618) | 0.0 % (0 / 413) | |||
Cancer | |||||||
Location | 0.45 | N/A | 97.0 % (392 / 404) | ||||
Colon | 69.7 % (435 / 624) | 71.1 % (3,465 / 4,870) | N/A | 74.6 % (308 / 413) | |||
Rectum | 28.2 % (176 / 624) | 26.7 % (1,298 / 4,870) | N/A | 25.4 % (105 / 413) | |||
Unknown | 2.1 % (13 / 624) | 2.2 % (107 / 4,870) | N/A | 0 % (0 / 413) | |||
AJCC collaborative stage | 0.70 | N/A | 95.2 % (393 / 413) | ||||
I | 30.0 % (187 / 624) | 31.0 % (1,511 / 4,870) | N/A | 30.5 % (126 / 413) | |||
II | 37.0 % (231/624) | 36.2 % (1,763 / 4,870) | N/A | 36.8 % (152 / 413) | |||
III | 33.0 % (206 / 624) | 32.7 % (1,596 / 4,870) | N/A | 32.7 % (135 / 413) | |||
Curative treatment - % (n / N) | |||||||
Surgical resection | 95.8 % (598 / 624) | N/A | 91.7 % (567 / 618) | 92.7 % (573 / 618) | N/A | N/A | |
Date of Surgery | N/A | 96.9 % (540 / 557) | N/A | N/A | |||
Neoadjuvant chemotherapy | 13.0 % (81 / 624) | N/A | 5.8 % (36 / 618) | 91.7 % (567 / 618) | N/A | N/A | |
Neoadjuvant radiation | 13.6 % (85 / 624) | N/A | 7.6 % (47 / 618) | 92.9 % (574 / 618) | N/A | N/A | |
Adjuvant chemotherapy | 27.1 % (169 / 624) | N/A | 30.1 % (186 / 618) | 81.6 % (504 / 618) | N/A | N/A | |
Adjuvant radiation | 5.6 % (35 / 624) | N/A | 21.8 % (135 / 618) | 80.3 % (496 / 618) | N/A | N/A |